Evidence map›Paper›PMID 41964892›Full record

ArticleWorld journal of urology2026

Risk factors for seminal vesicle invasion at radical prostatectomy.

Yu Ozawa, Marcio Covas Moschovas, Carlo Andrea Bravi, Marco Sandri, Rohan Sharma, Marco Montesi, Saleh Bubishate, Shady Saikali, Ari Diamond, Travis Rogers and 1 more

Abstract read
PubMed Publisher
In one paragraph

Article in World journal of urology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Yu OzawaAdventHealth Global Robotics Institute, 380 Celebration Pl Suite 401, Celebration, FL, 34747, USA. yu.ozawa0908@gmail.com.ORCID http://orcid.org/0000-0003-1633-784X
Marcio Covas MoschovasAdventHealth Global Robotics Institute, 380 Celebration Pl Suite 401, Celebration, FL, 34747, USA.
Carlo Andrea BraviDepartment of Urology, The Royal Marsden NHS Foundation Trust, London, UK.
Marco SandriBig and Open Data Innovation Laboratory (BODaI-Lab), University of Brescia, Brescia, Italy.
Rohan SharmaAdventHealth Global Robotics Institute, 380 Celebration Pl Suite 401, Celebration, FL, 34747, USA.
Marco MontesiAdventHealth Global Robotics Institute, 380 Celebration Pl Suite 401, Celebration, FL, 34747, USA.
Saleh BubishateAdventHealth Global Robotics Institute, 380 Celebration Pl Suite 401, Celebration, FL, 34747, USA.
Shady SaikaliAdventHealth Global Robotics Institute, 380 Celebration Pl Suite 401, Celebration, FL, 34747, USA.
Ari DiamondAdventHealth Global Robotics Institute, 380 Celebration Pl Suite 401, Celebration, FL, 34747, USA.
Travis RogersAdventHealth Global Robotics Institute, 380 Celebration Pl Suite 401, Celebration, FL, 34747, USA.
Vipul PatelAdventHealth Global Robotics Institute, 380 Celebration Pl Suite 401, Celebration, FL, 34747, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeTo comprehensively assess predictors of seminal vesicle invasion (SVI) at radical prostatectomy given the low sensitivity of magnetic resonance imaging (MRI).

methodsBetween 2017 and 2025, 4,448 patients underwent radical prostatectomy alone. Multivariable logistic regression was used to identify clinicopathological and MRI-related predictors of pathologic SVI, including age, Black race, PSA, PSA density, clinical T stage, Grade Group, percentage of positive cores, basal tumor involvement on systematic biopsy, the location of PI-RADS 4/5 lesions (apex/midgland/base), and MRI-suspected extracapsular extension and SVI. The same variables were evaluated in patients without MRI-detected SVI (n = 4,358). Model discrimination was assessed using the AUC.

resultsPathologic SVI prevalence was 6.9% (305/4,448). MRI demonstrated 17% sensitivity and 99% specificity. Independent clinicopathological predictors (all p < 0.04) were Black race (OR 1.48), log-PSA (OR 2.30/1-unit), Grade Groups 3–5 (OR 2.56–4.32), percentage of positive cores (OR 1.21/10%), and basal tumor involvement on biopsy (OR 1.92). MRI-related independent predictors (all p < 0.01) were SVI (OR 15.7), extracapsular extension (OR 1.69), and midgland (OR 1.49) and basal (OR 1.92) PI-RADS 4/5 lesions; apex lesions were inversely associated (OR 0.64). These associations remained significant in the MRI-negative subgroup. The model showed good discrimination (AUC 0.80, 95% CI 0.77–0.82), remaining robust in MRI-negative patients (AUC 0.76, 95% CI 0.73–0.79). Limitation included selection bias toward favorable-risk features by excluding patients with hormonal therapy.

conclusionMultifactorial risk assessment, particularly including tumor location, helps mitigate MRI’s limited sensitivity for SVI detection and could inform surgical or radiation planning in patients at risk of SVI.

Indexed as

ProstatectomyProstatic NeoplasmsSeminal VesiclesAgedHumansMagnetic Resonance ImagingMaleMiddle AgedNeoplasm InvasivenessRetrospective StudiesRisk FactorsBasal involvementGleason scoreLocally advancedNeoplasm recurrencepT3b prostate cancerRobot-assisted radical prostatectomy

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.